Quick Answer
Tango Therapeutics, Inc. reported Diluted EPS of $0.87 per share (loss) for fiscal year 2025.
Tango Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.87 | +26.9% |
| 2024 | -$1.19 | -10.2% |
| 2023 | -$1.08 | +12.2% |
| 2022 | -$1.23 | -30.9% |
| 2021 | -$0.94 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.13 | +148.1% | +137.1% |
| June 30, 2025 | -$0.35 | -45.8% | +2.8% |
| March 31, 2025 | -$0.36 | -2.9% | -33.3% |
| September 30, 2024 | -$0.27 | -17.4% | -12.5% |
| June 30, 2024 | -$0.24 | -4.3% | +31.4% |
| March 31, 2024 | -$0.35 | -9.4% | -52.2% |
| September 30, 2023 | -$0.23 | +30.3% | +0.0% |
| June 30, 2023 | -$0.23 | +17.9% | +28.1% |
- Tango Therapeutics, Inc. showed an increase of +26.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Tango Therapeutics, Inc.’s diluted eps has grown by 7.4% (from $0.94 per share (loss) to $0.87 per share (loss)).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: